Tizona
is a biotechnology company that researches, develops and commercializes immunotherapies for the treatment of cancer... Read moreTizona
is a biotechnology company that researches, develops and commercializes immunotherapies for the treatment of cancer... Read more
News
Nov 07, 2025
GlobalNewswire
Press Release: Tizona : Tizona Therapeutics Presents Clinical Translational Evidence of Dual Innate and Adaptive Immune Activation with TTX-080, a First-in-Class HLA-G Antagonist, in Patients with Advanced Solid Tumors at SITC 2025
Nov 01, 2024
Clinical Trials Arena
Tizona: Tizona's TTX-080 colorectal cancer trial expands with new arms
May 23, 2024
Benzinga
Tizona: Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024
Feb 07, 2024
BioCentury
Tizona: Tizona searching for new partner after Gilead declines buyout option
Oct 27, 2023
Pharamceutical Technology
Tizona: TTX-080 by Tizona Therapeutics for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Oct 14, 2021
Business Wire
Press Release: Tizona : Tizona Initiates Phase 1b Expansion Study of TTX-080 in Advanced Refractory or Resistant Malignancies
Sep 15, 2020
GlobalNewswire
Press Release: Tizona : Tizona Appoints Christine O'Brien as Chief Executive Officer
Jul 23, 2020
BioPharma-Reporter
Tizona: Gilead continues equity stake strategy with $300m deal
Jul 23, 2020
Global Legal Chronicle
Tizona: Gilead Sciences' $300 Million Acquisition of Tizona Therapeutics
Jul 22, 2020
The Pharma Letter
Tizona: Gilead takes another acquisition option punt, this one for Tizona
Tizona Competitors
1
2
3
4
5
6
7
8
9
10